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Background: RET rearrangement, a hallmark of radiation-induced 
thyroid cancer, has been reported to occur in 1% of lung adenocarci-
noma patients. Patients with this rearrangement tend to be younger 
and never smokers, raising a possibility of other causes, such as radi-
ation. We hypothesized that RET chromosomal rearrangement may 
represent a genetic mechanism of radiation-induced lung cancer.
Methods: Two hundred forty-five consecutive primary lung adeno-
carcinomas without history of radiation and 38 lung adenocarcinoma 
patients with a history of therapeutic radiation for breast carcinoma 
or mediastinal Hodkgin lymphoma were tested for RET rearrange-
ment by fluorescence in situ hybridization. Human lung adenocarci-
noma cells (201T) were subjected to γ radiation and tested for RET 
gene fusions by reverse transcriptase-polymerase chain reaction and 
Southern blot hybridization.
Results: We identified one case with RET rearrangement in the group 
without history of radiation (1 of 240; 0.4%) and two cases in the group 
with history of radiation (2 of 37; 5.4%; P=0.0436). Both these patients 
were women, who were former smokers with a history of breast carci-
noma treated with surgery and radiation. Furthermore, we found that RET 
fusions could be directly induced in 201T human lung cells by exposure to 
1 Gy of γ radiation. All fusions identified were between RET and KIF5B 
genes, and no RET fusions to CCDC6 or NCOA4 genes, characteristic for 
thyroid cancer, were identified in the irradiated lung cells.
Conclusion: RET fusions may represent a genetic mechanism of 
radiation-induced lung adenocarcinoma.
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Approximately 1% of lung adenocarcinomas were reported to harbor a novel gene fusion involving the RET tyrosine-
kinase gene partnered with either kinesin family member 
5B (KIF5B) or coiled-coil domain containing 6 (CCDC6).1–5 
RET is a receptor tyrosine-kinase involved in cell prolifera-
tion, migration, cell differentiation, and neuronal navigation. 
Germline and somatic mutations in RET are associated with 
multiple endocrine neoplasia type 2 and sporadic medullary 
carcinoma of thyroid. It is interesting that RET rearrange-
ments, mostly CCDC6-RET (papillary thyroid carcinoma 
[PTC1]) and nuclear receptor coactivator 4 (NCOA4) nuclear 
receptor coactivator 4 (NCOA4)-RET (PTC3), develop with 
a large prevalence in radiation-induced thyroid cancers.6 It is 
intriguing that patients with lung adenocarcinomas with RET 
fusion gene have a tendency to be younger and never-smok-
ers, raising a possibility of other causes, such as radiation. 
This is particularly likely because the RET gene rearrange-
ments represent a hallmark of radiation-induced cancer in the 
thyroid gland.7 Furthermore, exposure to radon is believed 
to be the second most common cause of lung cancer in the 
United States, and both medical therapeutic and accidental 
environmental irradiation are associated with the increased 
risk of lung cancer. The genetic mechanisms of radiation-
induced lung cancer are largely unknown. This led us to the 
hypothesis that RET chromosomal rearrangements represent 
a genetic mechanism of radiation-induced lung cancer.
PATIENTS AND METHODS
Patient Selection and Biomarker Testing
Two groups of patients were selected for the study. The 
first group included 245 consecutive newly diagnosed primary 
lung adenocarcinomas (stages I–IV). This group of patients 
had no documented history of medical, accidental, or profes-
sional irradiation. The second group included 38 lung cancer 
patients (stages I–IV) with the history of therapeutic radiation 
for breast carcinomas or mediastinal Hodkgin’s lymphomas 
at least 3 years before the diagnosis of lung cancer. The study 
was approved by the University of Pittsburgh Institutional 
Review Board (IRB #PRO12070216).
RET Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) analysis was 
performed by using standard method with the fusion probe for 
RET (Abnova, Taipei City, Taiwan) and paraffin pretreatment 
reagent kit (Vysis, Inc., Downers Grove, IL). At least 60 cells 
were scored for each case and control. Tumors with 12.8% or 
more of cells displaying RET rearrangement were classified as 
FISH positive. Each FISH assay included normal lung tissue 
sections as a negative control, and sections of lung non–small-
cell carcinoma previously identified with KIF5B-RET translo-
cation as a positive control.
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In Vitro Exposure to External γ Radiation and 
RET Rearrangements in Human Lung Cells
Human adenocarcinoma cells 201T (wild type for EGFR, 
KRAS, and met proto oncogene [MET]) were subjected to γ radi-
ation, a type of low-linear energy transfer (LET) radiation which 
is similar to radiographs used for radiotherapy.8 Cells (1 × 106) 
growing in T75 flasks were exposed to 1 Gy of γ radiation from 
Cs-137 delivered as a single dose by using the Gamma Cell 40 
(Nordion, Kanta, Ontario, Canada) irradiator split, into 30 flasks, 
grown for 8 days (~4 population doublings), and harvested.9 
Cell pellets were used to isolate RNA, purify mRNA, and test 
for RET gene fusions by reverse transcriptase polymerase chain 
reaction followed by Southern blot hybridization. Detection of 
RET/PTC1 and RET/PTC3 rearrangements was achieved using 
polymerase chain reaction primers reported before.10 This 
highly sensitive assay detects the formation of gene fusions 
with the rate as low as one in 106 cells. All experiments were 
performed in duplicate. Induction of DNA double-strand breaks 
(DSBs) was monitored by formation of γhistone H2AX foci. 
Cell survival was assessed using by counting floating cells and 
tryptan blue staining.
Statistical Analysis
Fisher’s exact probability test was used to compare the 
rates of positives between the groups. p Values less than 0.05 
were considered statistically significant.
RESULTS
Detection of RET Rearrangement 
in Patient Samples
FISH was successful in 240 cases of unselected, consec-
utively diagnosed lung adenocarcinomas. Technically subopti-
mal hybridization occurred in five samples. One of 240 cases 
(0.4%) was classified as positive for RET rearrangement, with 
15% of tumor cells showing the fused 3'5' RET and the split/
single 3' RET and the split/single 5' RET signal (Fig. 1).
Of 38 cases with a history of therapeutic radiation (dos-
age range, 40–60 Gy) there were 30 women with a history 
of breast cancer and eight men with a history of mediastinal 
Hodgkin’s lymphoma. All patients developed a primary lung 
adenocarcinoma. FISH assay was successful in 37 cases. Two 
of 37 cases (5.4%) were positive for RET rearrangement, with 
20.3% and 19.2% of the tumor cells showing FISH rearrange-
ment pattern. Both patients were women, who were former 
smokers with a history of breast carcinoma. The first patient 
received the 45 Gy dose followed by the 14 Gy boost to the 
tumor 5 years before the development of lung cancer. The 
second patient received the 50 Gy dose followed by the 10 
Gy boost to the tumor bed 7 years before the development of 
lung cancer. The difference in frequency of RET rearrange-
ment between the two study groups was statistically signifi-
cant (p=0.0436).
RET Rearrangements in Human Lung 
Cells Exposed to γ Radiation
We found that RET fusions could be directly induced 
in 201T human lung cells by 1 Gy of γ radiation. The induc-
tion of DSBs was confirmed by γH2AX nuclear foci forma-
tion (Fig. 2A). In both experimental replicates, we observed 
no formation of RET fusions in cells not exposed to radiation, 
whereas exposure to 1 Gy of radiation resulted in the forma-
tion of two KIF5B-RET fusions in each experiment involv-
ing 1 × 106 cells (Fig. 2B). Overall, five KIF5B/RET fusions 
were detected, with the following cDNA isoforms: exon 15 of 
KIF5B fused to exon 12 of RET (×3), exon 22 (×1), and exon 
23 (×1) (Table 1). No fusions was found between RET and 
either CCDC6 (RET/PTC1) or NCOA4 (RET/PTC3) genes, 
typical of radiation-associated thyroid cancer.10
DISCUSSION
The frequency of RET rearrangements in our unselected 
group of patients was lower than reported in literature. This 
could be explained by the fact that most reported stud-
ies are from Asia, and frequency of RET rearrangements 
in other racial and ethnical groups is still under investiga-
tion. Furthermore, our patient population tends to be older 
and having a history of smoking.11 Our preliminary data 
described above provide evidence that RET rearrangements 
occur with a significant frequency in lung adenocarcinomas 
from patients exposed to therapeutic radiation. Furthermore, 
we were able to induce RET fusions in human lung cells by γ 
radiation in vitro. This allowed us to propose the hypothesis 
that RET chromosomal rearrangement represents a genetic 
mechanism of radiation-induced lung cancer. Matsubara 
et al.12 recently reported the presence of CCDC6-RET fusion 
FIGURE 1. KIF5B/RET rearrange-
ment in the adenocarcinoma cells 
from a patient with a history of 
radiation therapy for breast cancer. 
Normal cells without rearrange-
ment show two red and two green 
signals separated, whereas cells 
with rearrangement show one red 
and one green signal separated and 
one pair of red and green signals in 
juxtaposition.
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in a lung carcinoma cell line. In contrast, our in vitro experi-
ments showed only KIF5B-RET fusions, and no fusions 
between RET and either CCDC6 or NCOA4 genes, which are 
typical of radiation-associated thyroid cancer. Our observa-
tions suggest that patients with radiation-induced lung can-
cer likely represent a subset of lung carcinoma patients who 
might benefit from clinically available tyrosine-kinase inhibi-
tors that target RET kinase activity.
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FIGURE 2. A, Generation of DSBs 
was monitored by formation of 
γH2AX nuclear foci. B, Induction 
of KIF5B/RET, but not CCDC6/RET 
or NCOA4/RET rearrangements in 
201T lung cells by γ radiation. 
TABLE 1.  Carcinogenic Rearrangements Detected in 201T Lung Cells
Sample ID Number of 
Cells Positive 
for gH2AX 
Foci
Number of Clones
Mutation Rate Per 106 CellsDetected by Hybridization
KIF5B/RET RET/PTC KIF5B/RET RET/PTC
K15/R12 K23/R12 K22/R12 PTC1 PTC3 K15/R12 K23/R12 K22/R12 PTC1 PTC3
0 Gy 5% 0 0 0 0 0 0 0 0 0 0
0 Gy 5% 0 0 0 0 0 0 0 0 0 0
1 Gy 100% 2 0 1 0 0 2 × 10−6 0 1 × 10−6 0 0
1 Gy 100% 1 1 0 0 0 1 × 10−6 1 × 10−6 0 0 0
